WO1999049882A3 - Vegf and vegf-c as infant formula supplements - Google Patents

Vegf and vegf-c as infant formula supplements Download PDF

Info

Publication number
WO1999049882A3
WO1999049882A3 PCT/US1999/006455 US9906455W WO9949882A3 WO 1999049882 A3 WO1999049882 A3 WO 1999049882A3 US 9906455 W US9906455 W US 9906455W WO 9949882 A3 WO9949882 A3 WO 9949882A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
infant
intestine
amount
sufficient
Prior art date
Application number
PCT/US1999/006455
Other languages
French (fr)
Other versions
WO1999049882A2 (en
Inventor
Dorothea J Eicher
Carol L Wagner
Charles Little
Original Assignee
Dorothea J Eicher
Carol L Wagner
Charles Little
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dorothea J Eicher, Carol L Wagner, Charles Little filed Critical Dorothea J Eicher
Priority to EP99914120A priority Critical patent/EP1121143A2/en
Priority to CA002331601A priority patent/CA2331601A1/en
Priority to AU32032/99A priority patent/AU3203299A/en
Publication of WO1999049882A2 publication Critical patent/WO1999049882A2/en
Publication of WO1999049882A3 publication Critical patent/WO1999049882A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition, comprising an amount of VEGF-C sufficient to stimulate lymphatic angiogenesis in an intestine is provided. A method of stimulating intestinal maturation in a premature infant, comprising administering to the infant an amount of the VEGF-C-containing composition sufficient to cause lymphatic angiogenesis in the infant's intestine is provided. A composition, comprising an amount of VEGF sufficient to stimulate vascular angiogenesis in an intestine is provided. A method of stimulating intestinal maturation in a premature infant, comprising administering to the infant an amount of the VEFG-containing composition sufficient to cause vascular angiogenesis in the infant's intestine is also provided.
PCT/US1999/006455 1998-03-27 1999-03-26 Vegf and vegf-c as infant formula supplements WO1999049882A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99914120A EP1121143A2 (en) 1998-03-27 1999-03-26 Vegf and vegf-c as infant formula supplements
CA002331601A CA2331601A1 (en) 1998-03-27 1999-03-26 Vegf and vegf-c as infant formula supplements
AU32032/99A AU3203299A (en) 1998-03-27 1999-03-26 Vegf and vegf-c as infant formula supplements

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7970798P 1998-03-27 1998-03-27
US60/079,707 1998-03-27

Publications (2)

Publication Number Publication Date
WO1999049882A2 WO1999049882A2 (en) 1999-10-07
WO1999049882A3 true WO1999049882A3 (en) 2001-05-17

Family

ID=22152277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006455 WO1999049882A2 (en) 1998-03-27 1999-03-26 Vegf and vegf-c as infant formula supplements

Country Status (4)

Country Link
EP (1) EP1121143A2 (en)
AU (1) AU3203299A (en)
CA (1) CA2331601A1 (en)
WO (1) WO1999049882A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
SE535296C2 (en) 2010-09-08 2012-06-19 Anara Ab Maturation of the gastrointestinal tract
US20140286908A1 (en) * 2011-10-18 2014-09-25 Nestec S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c
WO1998046249A1 (en) * 1997-04-15 1998-10-22 Radix Organization, Inc. Method of treating gastrointestinal ulcers and compositions therefor
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005250A2 (en) * 1995-08-01 1997-02-13 Helsinki University Licensing Ltd. Oy Receptor ligand vegf-c
WO1998046249A1 (en) * 1997-04-15 1998-10-22 Radix Organization, Inc. Method of treating gastrointestinal ulcers and compositions therefor
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. MAGOVERN ET AL.: "Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor.", HUMAN GENE THERAPY, vol. 8, 20 January 1997 (1997-01-20), New York, NY, USA, pages 215 - 227, XP002064914 *
D. EICHER ET AL.: "Vascular endothelial growth factor (VEGF) is present in human milk.", PEDIATRIC RESEARCH, vol. 41, no. 4 part 2, 1997, Baltimore, MD, USA, pages 82A, XP002118193 *
M. SRIVASTAVA ET AL.: "Vascular endothelial growth factor in human milk.", MEDICAL SCIENCE RESEARCH, vol. 26, no. 6, June 1998 (1998-06-01), Essex, GB, pages 419 - 421, XP002118195 *
V. JOUKOV ET AL.: "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.", THE EMBO JOURNAL, vol. 15, no. 2, 15 January 1996 (1996-01-15), Oxford, GB, pages 290 - 298, XP002118194 *

Also Published As

Publication number Publication date
CA2331601A1 (en) 1999-10-07
AU3203299A (en) 1999-10-18
EP1121143A2 (en) 2001-08-08
WO1999049882A2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
EP0784429A4 (en) Method and formulation of stimulating nitric oxide synthesis
CA2231292A1 (en) Method for decreasing ldl-cholesterol concentration and increasing hdl-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
BG103647A (en) Cisplatina containing microgranules
MY109309A (en) Improvements in or relating to somatostatins
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
PL338126A1 (en) Treatment of diabetes by means of derivatives of thiazolydinone, of insulin secretion stimulating agent and of biguanidinic derivative
ZA984268B (en) Method and composition for administering taxanes orally to human patients
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
NZ233912A (en) Pyridazinyl-3-oxy substituted chroman derivatives, pharmaceutical compositions, methods of treatment and preparation
WO1999049882A3 (en) Vegf and vegf-c as infant formula supplements
IE890580L (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
ZA883744B (en) Promotion of healing of meniscal tissue
ZA967319B (en) Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
AR243081A1 (en) Synthetic vaccins against foot and mouth disease and their preparation process
ZA879452B (en) 5-hydroxyethyl derivatives of oxazolidinone-2,their preparation and their therapeutic uses
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
PH24977A (en) Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2h-1-benzopyran derivatives
JPS6438073A (en) Novel derivative of tetrahydropyridine, manufacture and intermediate, use as drug and medicinal composition
GB0120124D0 (en) Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
FR2770976B1 (en) FOOD SUPPLEMENT FORMULA COMBINING PLANT (DIOSCOREACAE) VITAMINS AND / OR TRACE ELEMENTS TO STIMULATE THE VITALITY OF THE HUMAN ORGANISM
SK60995A3 (en) Nutritive preparation for younglings of ruminants
ZA87444B (en) 3-(acylaminomethyl)imidazo(1,2-a)pyridine derivatives,their preparation and their application in therapy
IL84777A (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999914120

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 32032/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2331601

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09647324

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999914120

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999914120

Country of ref document: EP